Rituximab: all 1,389 studies that test it

Page 3 of 14. Open to participants first (177), then studies with results posted, then the rest; newest registration first within each.

• Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell LeukemiaActive, not recruitingNCT03805932Phase 1Results posted
• Response-Adapted Therapy With Copanlisib and Rituximab in Untreated Follicular LymphomaActive, not recruitingNCT03789240Phase 2Results posted
• Acalabrutinib and High Frequency Low Dose Subcutaneous Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia / Small Lymphocytic LymphomaCompletedNCT03788291Phase 2Results posted
• Ibrutinib Plus Rituximab for cGVHD Following Allo-SCTTerminatedNCT03689894Phase 1/2Results posted
• Rituximab + Immunotherapy in Follicular LymphomaTerminatedNCT03636503Phase 1Results posted
• Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's MacroglobulinaemiaCompletedNCT03630042Phase 2Results posted
• Acalabrutinib With Bendamustine / Rituximab Followed by Cytarabine / Rituximab for Untreated Mantle Cell LymphomaCompletedNCT03623373Phase 2Results posted
• Bendamustine/Rituximab Followed by Venetoclax and Rituximab for Treatment of Chronic Lymphocytic LeukemiaCompletedNCT03609593Phase 2Results posted
• Cardiac Safe Transplants for Systemic SclerosisTerminatedNCT03593902Phase 2/3Results posted
• BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL)CompletedNCT03520920Phase 2Results posted
• Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell LymphomaTerminatedNCT03401853Phase 2Results posted
• A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLLActive, not recruitingNCT03336333Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Belimumab Administered in Combination With Rituximab to Adult Subjects With Systemic Lupus Erythematosus (SLE) - BLISS-BELIEVECompletedNCT03312907Phase 3Results posted
• Carfilzomib With or Without Rituximab in the Treatment of Waldenstrom Macroglobulinemia or Marginal Zone LymphomaTerminatedNCT03269552Phase 2Results posted
• Ibrutinib, Rituximab, Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride in Treating Patients With HIV-Positive Stage II-IV Diffuse Large B-Cell LymphomasActive, not recruitingNCT03220022Phase 1Results posted
• A Study of Obinutuzumab in Combination With Idasanutlin and Venetoclax in Participants With Relapsed or Refractory (R/R) Follicular Lymphoma (FL) or Rituximab in Combination With Idasanutlin and Venetoclax in Participants With R/R Diffuse Large B-Cell Lymphoma (DLBCL)TerminatedNCT03135262Phase 1/2Results posted
• Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients With Leukemia or LymphomaCompletedNCT03096782Phase 2Results posted
• Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's LymphomaCompletedNCT03019640Phase 2Results posted
• Comparison of Clinical Effects of Azathioprine and Rituximab NMO-SD PatientsCompletedNCT03002038Phase 2/3Results posted
• A Study of TAK-659 in Combination With Bendamustine (+/-Rituximab), Gemcitabine, Lenalidomide, or Ibrutinib for the Treatment of Participants With Advanced Non-Hodgkin LymphomaTerminatedNCT02954406Phase 1Results posted
• Avelumab In Combination Regimens That Include An Immune Agonist, Epigenetic Modulator, CD20 Antagonist and/or Conventional Chemotherapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (R/R DLBCL)TerminatedNCT02951156Phase 3Results posted
• A Study Evaluating the Safety and Efficacy of Rituximab in Patients With Myasthenia GravisCompletedNCT02950155Phase 3Results posted
• Lenalidomide Combined With Modified DA-EPOCH and Rituximab (EPOCH-R2) in Primary Effusion Lymphoma or KSHV-associated Large Cell LymphomaActive, not recruitingNCT02911142Phase 1/2Results posted
• Lenalidomide, Ixazomib, and Rituximab as Front-Line Therapy for High Risk Indolent B-Cell LymphomaTerminatedNCT02898259Phase 1/2Results posted
• Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone LymphomaCompletedNCT02853370Phase 2Results posted
• PK, PD, Safety, and Efficacy of SAIT101 Versus MabThera® Versus Rituxan® in Patients With Rheumatoid ArthritisCompletedNCT02819726Phase 1Results posted
• A Randomized, Double-blind, Multi-center, Multi-national Trial to Evaluate the Efficacy, Safety, and Immunogenicity of SAIT101 Versus Rituximab as a First-line Immunotherapy Treatment in Patients With Low Tumor Burden Follicular LymphomaCompletedNCT02809053Phase 3Results posted
• Study to Assess if ABP 798 is Safe & Effective in Treating Moderate to Severe Rheumatoid Arthritis (RA) Compared to RituximabCompletedNCT02792699Phase 3Results posted
• Maintenance of ANCA Vasculitis Remission by Intermittent Rituximab DosingTerminatedNCT02749292Phase 4Results posted
• Study to Assess if ABP798 is Safe & Effective in Treating Non Hodgkin Lymphoma Compared to RituximabCompletedNCT02747043Phase 3Results posted
• A Study Evaluating Safety and Efficacy of Obinutuzumab, Polatuzumab Vedotin (Pola), and Atezolizumab (Atezo) in Participants With Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab, Atezo, and Pola in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT02729896Phase 1/2Results posted
• Ibrutinib in Patients With Refractory/Relapsed Non-GCB Diffuse Large B-cell Lymphoma Non-candidates to ASCTCompletedNCT02692248Phase 2Results posted
• TCR-α/β and CD19 Depleted Stem Cell Grafts From Haplo Donors for HSCT in Relapsed LymphomaCompletedNCT02652468Not applicableResults posted
• Safety and Efficacy Study of Subcutaneous Belimumab and Intravenous Rituximab Co-administration in Subjects With Primary Sjogren's SyndromeCompletedNCT02631538Phase 2Results posted
• R-ICE and Lenalidomide in Treating Patients With First-Relapse/Primary Refractory Diffuse Large B-Cell LymphomaActive, not recruitingNCT02628405Phase 1/2Results posted
• A Study of Idasanutlin in Combination With Obinutuzumab in Relapsed/Refractory (R/R) Follicular Lymphoma (FL) and in Combination With Rituximab in R/R Diffuse Large B-Cell Lymphoma (DLBCL) ParticipantsTerminatedNCT02624986Phase 1/2Results posted
• MabionCD20 Compared to MabThera in Lymphoma PatientsCompletedNCT02617485Phase 3Results posted
• A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT02611323Phase 1/2Results posted
• A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) and Rituximab in Combination With Polatuzumab Vedotin and Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT02600897Phase 1/2Results posted
• A Study of Atezolizumab in Combination With Either Obinutuzumab Plus Bendamustine or Obinutuzumab Plus (+) Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Participants With Follicular Lymphoma (FL) or Rituximab + CHOP in Participants With Diffuse Large B-Cell Lymphoma (DLBCL)CompletedNCT02596971Phase 1/2Results posted
• A Phase I Dose Escalation Study of the Safety and Pharmacokinetics of LAM-002A In Patients With Non-Hodgkin's LymphomaCompletedNCT02594384Phase 1Results posted
• A Study of Long-Term Rituximab (MabThera) Maintenance Therapy in Participants With Advanced Follicular LymphomaCompletedNCT02569996Phase 3Results posted
• Study to Evaluate the Efficacy and Tolerability of Debio 1562 in Combination With Rituximab in Participants With Relapsed and/or Refractory DLBCL and Other Forms of NHLCompletedNCT02564744Phase 2Results posted
• A Study of Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)CompletedNCT02533401Phase 2Results posted
• Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone LymphomaCompletedNCT02532257Phase 2Results posted
• GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera®CompletedNCT02514772Phase 3Results posted
• Study of Intratumoral G100 With Or Without Pembrolizumab or Rituximab In Participants With Follicular Non-Hodgkin's Lymphoma (MK-3475-174/IMDZ-G142)TerminatedNCT02501473Phase 1/2Results posted
• Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients With Non-Hodgkin LymphomaStatus unknownNCT02481310Phase 1/2Results posted
• Lirilumab With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) PatientsCompletedNCT02481297Phase 2Results posted
• Dose Finding Study of Ibrutinib Plus Lenalidomide / Rituximab in Relapsed or Refractory Mantle Cell LymphomaActive, not recruitingNCT02446236Phase 1Results posted
• BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular LymphomaTerminatedNCT02417129Phase 3Results posted
• Safety Study of Rituximab (SC) Administered in Participants With CD20+ DLBCL or CD20+ Follicular NHL Grade 1 to 3ACompletedNCT02406092Phase 3Results posted
• Trial of Ixazomib, Dexamethasone and Rituximab in Patients With Untreated Waldenstrom's MacroglobulinemiaCompletedNCT02400437Phase 2Results posted
• A Study of Duvelisib in Combination With Rituximab or Obinutuzumab in Subjects With Previously Untreated CD20+ Follicular Lymphoma (CONTEMPO)TerminatedNCT02391545Phase 1/2Results posted
• Randomized Trial Comparing Rituximab Against Mycophenolate Mofetil in Children Wtih Refractory Nephrotic SyndromeTerminatedNCT02390362Phase 3Results posted
• QUILT-3.002: N-803 in Patients With Relapse/Refractory iNHL in Conjunction With RituximabTerminatedNCT02384954Phase 1/2Results posted
• A Study to Evaluate the Efficacy and Safety of Rituximab Versus Mycophenolate Mofetil (MMF) in Participants With Pemphigus Vulgaris (PV)CompletedNCT02383589Phase 3Results posted
• Rituximab (RTX) Therapy in Patients With Active TAOCompletedNCT02378298Phase 4Results posted
• BEAM vs. 90-Yttrium Ibritumomab Tiuxetan (Zevalin®)/BEAM With ASCT for Relapsed DLBCLTerminatedNCT02366663Phase 3Results posted
• Study Evaluating the Safety and Efficacy of KTE-C19 in Adult Participants With Refractory Aggressive Non-Hodgkin LymphomaCompletedNCT02348216Phase 1/2Results posted
• Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin LymphomaActive, not recruitingNCT02339922Phase 2Results posted
• Stem Cell Transplantation for Stiff Person Syndrome (SPS)TerminatedNCT02282514Phase 1/2Results posted
• Study of RTXM83 Plus CHOP Chemotherapy Versus a Rituximab Plus CHOP Therapy in Patients With Non Hodgkin's LymphomaCompletedNCT02268045Phase 3Results posted
• B Cell Induction in Pediatric Lung TransplantationCompletedNCT02266888Phase 2Results posted
• To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular LymphomaCompletedNCT02260804Phase 3Results posted
• Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic LymphomaTerminatedNCT02258529Phase 2Results posted
• A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell LymphomaCompletedNCT02257567Phase 1/2Results posted
• Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab-Phase I Trial in Indolent B-cell LymphomaCompletedNCT02257242Phase 1Results posted
• A Phase II Study of Ibrutinib Plus FCR in Previously Untreated, Younger Patients With Chronic Lymphocytic LeukemiaActive, not recruitingNCT02251548Phase 2Results posted
• A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera® (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive, Low Tumor Burden, Follicular Lymphoma (REFLECTIONS B328-06)CompletedNCT02213263Phase 3Results posted
• A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal AntibodiesTerminatedNCT02205333Phase 1/2Results posted
• Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic LeukemiaCompletedNCT02199184Phase 2Results posted
• Pilot Study of Rituximab to Treat Fibrillary GlomerulonephritisCompletedNCT02197767Phase 2Results posted
• Pilot Study of Short-Course Glucocorticoids and Rituximab for Treatment of ANCA-Associated VasculitisCompletedNCT02169219Phase 4Results posted
• Ibrutinib With Rituximab in Adults With Waldenström's MacroglobulinemiaCompletedNCT02165397Phase 3Results posted
• To Demonstrate Equivalence of Pharmacokinetics and Noninferiority of Efficacy for CT-P10 in Comparison With RituxanCompletedNCT02162771Phase 3Results posted
• A Phase 1b/2 Study of IPI-145 Plus FCR in Previously Untreated, Younger Patients With CLLActive, not recruitingNCT02158091Phase 1/2Results posted
• ADAM17 Inhibitor/ Rituximab After Auto HCT for DLBCLCompletedNCT02141451Phase 1/2Results posted
• BeatMG: Phase II Trial of Rituximab In Myasthenia GravisCompletedNCT02110706Phase 2Results posted
• A Study of the Efficacy and Safety of Re-treatments With Rituximab in Patients With Active Rheumatoid Arthritis Who Have Had an Inadequate Response to Anti-tnfa TherapiesCompletedNCT02097745Phase 3Results posted
• Extension Study to Assess the Efficacy and Safety of Repeat Treatment With Rituximab (MabThera) in Participants With Active Rheumatoid Arthritis (RA)CompletedNCT02093026Phase 2Results posted
• A Phase 2 Clinical Trial of Rituxan and B-Glucan PGG in Relapsed Indolent Non-Hodgkin LymphomaCompletedNCT02086175Phase 2Results posted
• A Study of MabThera (Rituximab) in Patients With Rheumatoid Arthritis Who Have Had an Inadequate Response to a Single Anti-TNF InhibitorCompletedNCT02079532Phase 3Results posted
• Ibrutinib in Combination With Lenalidomide and Rituximab in Participants With Relapsed or Refractory Diffuse Large B-Cell LymphomaCompletedNCT02077166Phase 1/2Results posted
• Carfilzomib, Rituximab, and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell LymphomaCompletedNCT02073097Phase 1/2Results posted
• A Study Evaluating the Safety, Efficacy and Pharmacokinetics of Venetoclax Combined With Chemotherapy in Participants With B-Cell Non-Hodgkin's Lymphoma (NHL) and DLBCLCompletedNCT02055820Phase 1/2Results posted
• Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p DeletionTerminatedNCT02044822Phase 2Results posted
• Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune DiseasesCompletedNCT02040116Phase 4Results posted
• CHAIROS Study A Study of MabThera/Rituxan (Rituximab) Maintenance Therapy in Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Naive to ChemotherapyCompletedNCT02013817Phase 2Results posted
• A Study of MabThera/Rituxan (Rituximab) in Combination With Methotrexate in Patients With Rheumatoid Arthritis and Inadequate Response to DMARD TherapyCompletedNCT02006706Phase 3Results posted
• A Study of MabThera/Rituxan (Rituximab) in Patients With Relapsed Centroblastic Centrocytic Non-Hodgkin's LymphomaCompletedNCT01998893Phase 2Results posted
• Lenalidomide Plus Rituximab Followed by Lenalidomide Versus Rituximab Maintenance for Relapsed/Refractory Follicular, Marginal Zone or Mantle Cell Lymphoma.CompletedNCT01996865Phase 3Results posted
• A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's LymphomaCompletedNCT01992653Phase 1/2Results posted
• MabRella Study: A Study to Evaluate the Safety of Switching From Intravenous to Subcutaneous Administration of Rituximab During First-Line Treatment for LymphomaCompletedNCT01987505Phase 3Results posted
• Study of Ibrutinib in Combination With Rituximab in Previously Untreated Subjects With Follicular LymphomaCompletedNCT01980654Phase 2Results posted
• A Study of PCI-32765 (Ibrutinib) Versus Rituximab in Relapsed or Refractory Chronic Leukemia/LymphomaCompletedNCT01973387Phase 3Results posted
• Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Primary Central Nervous System Non-Hodgkin LymphomaTerminatedNCT01973062Phase 2Results posted
• Autoantibody Reduction Therapy in Patients With Idiopathic Pulmonary FibrosisCompletedNCT01969409Phase 2Results posted
• Carfilzomib, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Stage I-IV Diffuse Large B-cell LymphomaActive, not recruitingNCT01959698Phase 1Results posted
• Safety and Efficacy of BI 695500 in Patients With Moderately to Severely Active Rheumatoid ArthritisTerminatedNCT01955733Phase 3Results posted

← Rituximab overview